GentiBio
Brian Christin is Senior Director and CMC Strategy Lead at GentiBio. Brian has experience advancing multiple cell therapy programs through clinical and commercial development during his time at Dendreon, Juno Therapeutics, Celgene, and Bristol Myers Squibb. Most recently, Brian was the Senior Director of Cell Therapy Product Stewardship at Bristol Myers Squibb (previously Celgene, Juno Therapeutics) where he led a team that maintained technical accountability for approval, launch, and post-approval lifecycle management of the commercial Breyanzi and Abecma programs and supported the advancement of multiple early phase cell therapy programs. Born and raised in the Seattle area, Brian stayed in the Pacific Northwest and obtained a BS in Chemical Engineering from the University of Washington (Go Dawgs!).
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.